Bharat Biotech on Wednesday signed a licensing agreement with Washington University School of Medicine in St Louis, US for a novel “chimp-adenovirus”, single dose intranasal vaccine for COVID-19.
According to a press release issued by the city-based vaccine maker, Bharat Biotech owns the rights to distribute the vaccine in all markets except the US, Japan and Europe.
While the Phase I trial will take place in St Louis University’s Vaccine and Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility in Genome Valley here, it said.
Adenoviruses are the basis for many investigational vaccines for COVID-19 and other infectious diseases, such as Ebola virus and tuberculosis. They have good safety and efficacy records, but not much research has been done with nasal delivery of these vaccines.
“Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines.
It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 which reaches all citizens of the world,” Chairman and Managing Director of Bharat Biotech, Krishna Ella said.
The company envisions to scale up this vaccine to one billion doses, translating to an equal number of individuals vaccinated receiving a single-dose regimen.